文献速递肝病消化道肿瘤与早癌

GALAD评分在国际非酒精性脂肪性肝炎队列中检测早期肝细胞癌

GALAD Score Detects Early Hepatocellular Carcinoma in an International Cohort of Patients With Nonalcoholic Steatohepatitis.
PubMed 文献 · Clin Gastroenterol Hepatol · 2019-11-08

该研究在德国8中心125例HCC和231例NASH对照中验证GALAD评分,并在日本389例NASH监测队列中评估其提前预警能力。GALAD评分检测任何分期HCC的AUC为0.96,优于AFP、AFP-L3和DCP;检测米兰标准内HCC的AUC为0.91,切点-0.63时灵敏度68%、特异度95%。日本队列中GALAD评分在HCC诊断前约200天已超过-0.63。

要点

  • GALAD评分检测NASH相关HCC的AUC达0.96,优于单一血清标志物。
  • 检测米兰标准内HCC的AUC为0.91,切点-0.63时灵敏度68%、特异度95%。
  • GALAD评分可在HCC诊断前约200天超过-0.63,有早期预警潜力。

核心结论

  • GALAD评分在伴或不伴肝硬化的NASH患者中均能以高准确度检测HCC,并可检测早期HCC。

研究设计与样本

  • 德国8中心病例对照研究纳入125例HCC患者(20%在米兰标准内)和231例无HCC的NASH对照。
  • 日本NASH监测队列纳入389例患者,中位随访167个月,5年筛查期间26例发生HCC。

主要发现

  • GALAD评分检测任何分期HCC的AUC为0.96,显著高于AFP的0.88、AFP-L3的0.86和DCP的0.87。
  • GALAD评分在肝硬化患者中AUC为0.93,无肝硬化患者中AUC为0.98。
  • 检测米兰标准内HCC时,GALAD评分AUC为0.91,切点-0.63时灵敏度68%、特异度95%。
  • 日本队列中发生HCC的NASH患者平均GALAD评分在诊断前1.5年即高于未发生者,约诊断前200天超过-0.63。

关键数值与推荐

  • GALAD评分基于性别、年龄及血清AFP、AFP-L3和DCP水平计算HCC风险。
  • 检测米兰标准内HCC的切点为-0.63,对应灵敏度68%、特异度95%。

临床怎么用

  • GALAD评分可用于NASH患者HCC监测,尤其肥胖患者超声敏感性受限时。
  • GALAD评分可在HCC诊断前约200天提示风险升高,有助于早期发现。

局限性

  • 德国部分为病例对照设计,日本部分为试点队列,需进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: The prevalence of nonalcoholic steatohepatitis (NASH) associated hepatocellular carcinoma (HCC) is increasing. However, strategies for detection of early-stage HCC in patients with NASH have limitations. We assessed the ability of the GALAD score, which determines risk of HCC based on patient sex; age; and serum levels of α-fetoprotein (AFP), AFP isoform L3 (AFP-L3), and des-gamma-carboxy prothrombin (DCP), to detect HCC in patients with NASH. METHODS: We performed a case-control study of 125 patients with HCC (20% within Milan Criteria) and 231 patients without HCC (NASH controls) from 8 centers in Germany. We compared the performance of serum AFP, AFP-L3, or DCP vs GALAD score to identify patients with HCC using receiver operating characteristic curves and corresponding area under the curve (AUC) analyses. We also analyzed data from 389 patients with NASH under surveillance for HCC in Japan, followed for a median of 167 months. During the 5-year screening period, 26 patients developed HCC. To compensate for irregular intervals of data points, we performed locally weighted scatterplot smoothing, linear regression, and a non-linear curve fit to assess development of GALAD before HCC development. RESULTS: The GALAD score identified patients with any stage HCC with an AUC of 0.96 - significantly greater than values for serum levels of AFP (AUC, 0.88), AFP-L3 (AUC, 0.86) or DCP (AUC, 0.87). AUC values for the GALAD score were consistent in patients with cirrhosis (AUC, 0.93) and without cirrhosis (AUC, 0.98). For detection of HCC within Milan Criteria, the GALAD score achieved an AUC of 0.91, with a sensitivity of 68% and specificity of 95% at a cutoff of -0.63. In a pilot Japanese cohort study, the mean GALAD score was higher in patients with NASH who developed HCC than in those who did not develop HCC as early as 1.5 years before HCC diagnosis. GALAD scores were above -0.63 approximately 200 days before the diagnosis of HCC. CONCLUSIONS: In a case-control study performed in Germany and a pilot cohort study in Japan, we found the GALAD score may detect HCC with high levels of accuracy in patients with NASH, with and without cirrhosis. The GALAD score can detect patients with early-stage HCC, and might facilitate surveillance of patients with NASH, who are often obese, which limits the sensitivity of detection of liver cancer by ultrasound.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Best J, Bechmann LP, Sowa JP, et al. GALAD Score Detects Early Hepatocellular Carcinoma in an International Cohort of Patients With Nonalcoholic Steatohepatitis. Clin Gastroenterol Hepatol. 2019. PMID: 31712073. doi:10.1016/j.cgh.2019.11.012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。